

Dysregulated S1P Signalling in a Mouse Model of Cystic Fibrosis-like Lung Disease Produced by β -ENaC Overexpression


INTRODUCTION

- Cystic fibrosis (CF)** is a life-threatening, multi-organ disease. The lung is the primary target, and results in the largest morbidity and mortality.
- Epithelial dehydration via defective CFTR activity results in the hallmark **mucus obstruction** and chronic, destructive **pro-inflammatory conditions** in the lower airways.
- Prior studies suggest that mechanisms of **CF** may include **dysregulated sphingolipid signalling**^{1,2}.

Inflammation

- CF lungs exhibit elevated levels of IL-1 β , TNF α , IL-6, and IL-8.
- IL-1 β** is controlled via activation of **inflammasomes**; cytosolic multiprotein complexes aggregated around a sentinel protein, e.g. NLRP3.
- NLRP3 inflammasome** strongly implicated in CF³, but unclear whether this is due to CF or downstream stimuli such as pathogen presence, e.g. *P. aeruginosa*.

Sphingolipids and S1P



- Sphingosine-1-phosphate (**S1P**) is a small, bioactive lipid that regulates many cellular processes and is important in airway diseases⁴.
- S1P is generated in cells from sphingosine by SPHK1 and SPHK2.**
- It acts on intracellular and membrane-bound receptors (S1PRs), and can be **exported from the cell by SPNS2** (Spinster homologue 2) where it can act via autocrine and paracrine signalling.
- S1P opposes sphingosine and ceramide** from which it is derived \rightarrow this balance is known as the sphingosine rheostat.
- Ceramide has been identified as a potential cause of **cell death, inflammation, and infection susceptibility** in CF patients and *CFTR* mutant mice.

We therefore assessed a **CF-like** mouse model (**β ENaC**) for its efficacy for further investigations into potential S1P dysregulation in CF disease.

β ENaC MODEL

- Transgenic mouse model over-expressing the β -subunit of the epithelial sodium channel (ENaC).
 - Mimics the Na⁺ ion transport abnormalities observed in CF airways.
 - Increased Na⁺ absorption \rightarrow depletion of airway surface liquid and deficient mucus clearance.
- Exhibit **CF-like** lung disease features⁵:
 - Mucus hypersecretion.
 - Mucus obstruction in the conducting airways.
 - Mucociliary clearance impairment.
 - Goblet cell metaplasia.
 - Airway inflammation.
 - Poor bacterial clearance following intra-tracheal pathogen challenge with *H. influenzae* and *P. aeruginosa*.
- Is reported to be a relevant model for investigating certain elements of CF lung disease⁵.




METHODS

- Archived mouse lung tissue sections from β ENaC mice and wild-type littermates were retrieved. Section availability varied by individual mouse ID, sometimes altering n values.
- Tissue sections were stained for key proteins and observed by immunofluorescence via confocal microscopy at 60x objective magnification. Mucus obstruction and plugs were identified by Alcian Blue/PAS staining and microscopy.


RESULTS

Confirmation of Mucus Obstruction in Conducting Airways


β ENaC Airways (Alcian Blue/PAS) – Mucus Obstruction (left) & Plugging (right)



Wild-Type Airways (Alcian Blue/PAS)




BV: Blood Vessel
Black arrows: conducting airways




As previously shown, β ENaC mice develop certain **hallmark characteristics of CF** such as mucus accumulation and obstruction of the airways. In the mice examined, **approximately 25.3% of the conducting airways showed some degree of mucus accumulation.**

Inflammatory Airway Environment with β ENaC Over-Expression

TNF α Immunofluorescence Images of Mouse Lungs



Blue: DAPI staining of nuclei; White arrows: mucus




* = p < 0.05; ** = p < 0.01

The **inflammatory cytokine TNF α** was overexpressed in **conducting airways of β ENaC mice**, irrespective of mucus obstruction. The number of TNF α immunofluorescence bright spots and their average size were similar in these mice, while control mice bronchioles showed only dull staining.

REFERENCES

- Teichgraber V et al., 2008. 'Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis,' *Nat Med* 14(4): 382-391.
- Ebenezer DL et al., 2016. 'Targeting sphingosine-1-phosphate signalling in lung diseases,' *Pharmacol Ther* 168: 143-157.
- Iannitti RG et al., 2016. 'IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis,' *Nat Commun* 7:10791.
- Maceyka M et al., 2012. 'Sphingosine-1-phosphate signalling and its role in disease,' *Trends Cell Biol*, 22(1): 50-60.
- Mall M et al., 2004. 'Increased airway epithelial Na⁺ absorption produces cystic fibrosis-like lung disease in mice,' *Nat Med* 10:487-493.
- Baroja-Mazo A, 2014. 'The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response,' *Nat Immunol* 15: 738-748.

Inflammatory Airway Environment with β ENaC Over-Expression




Blue: DAPI staining of nuclei; White arrows: mucus


NLRP3 significantly increased in β ENaC mice with mucus presence with some extracellular localisation in bronchiole lumen; NLRP3 reportedly released by cells where it acts an extracellular oligomeric complex to amplify the inflammatory response⁶. **Downstream IL-1 β** also showed significantly increased levels.

Suggests while β ENaC mice demonstrate genotypic increases in inflammation, inflammasome-mediated inflammation may relate to airway mucus presence.

SPNS2 Expression Reduced in Mucus Obstructed β ENaC Airways



** = p < 0.01; *** = p < 0.001 Spearman r: unobstructed: 0.5797; mucus plug: 0.6944



Blue: DAPI staining of nuclei; White arrows: mucus

Mucus presence significantly decreases expression of SPNS2 in β ENaC mice in addition to a **trend for decreased SPHK1 expression**; the **expression levels of these proteins are significantly correlated.**

CONCLUSIONS

- The β ENaC model successfully developed some CF-like characteristics, particularly in regard to mucus and inflammation.
- Mucus-related downregulation of SPHK1 and SPNS2 may point to dysregulation of the S1P pathway.
 - Potential intracellular build-up of S1P (need to test S1P phosphatase levels (SGPP1); reverses action of SPHK1).
- As this model does not involve dysfunctional CFTR, we aim to compare it with a *CFTR*^{-/-} KO rat model to determine its efficacy for S1P signalling experiments.